Using a preclinical model system of Fragile X Syndrome (FXS), the proposed studies will identify new auditory processing based biomarkers that can be used as reliable outcome measures for therapeutics and provide new insights into neural mechanisms underlying auditory hypersensitivity in FXS. FXS is the most common inherited cause of mental impairment, and is a leading genetic cause of autism. Data from humans with FXS and the mouse model (Fmr1 KO) indicate auditory processing deficits. In vivo electrophysiological data from cortical neurons in adult Fmr1 KO mice suggest hyper-excitability in response to sounds and altered spectral and temporal responses. The proposed studies will determine the developmental time course of auditory cortical deficits in Fmr1 knock out (KO) mice, address mechanisms of these deficits and evaluate novel drugs in treating auditory functional deficits.
Specific aim 1 will test the hypothesis that auditory processing deficits in the adult Fmr1 KO mice arise due to a deficit in developmental refinement of cortical processing. These studies will also compare auditory cortical responses between mice in which Fmr1 is deleted only in the excitatory neurons to address sources of deficits. In addition, recordings will be obtained from mice in which cortical Fmr1 is deleted only from 3 weeks postnatal to disambiguate developmental versus acute role for Fmr1 in establishing cortical responses in adult mice. Dendritic spine morphology of Al neurons will also be tracked during development to identify possible structural correlates of functional deficits.
Specific aim 2 will determine baseline and sound evoked electroencephalogram (EEG) responses in awake, behaving mice. We will determine the effect of candidate drugs in reversing the auditory deficits at the single neuron and EEG/ERP levels. The EEG response will provide high throughput markers to test drugs. These studies will also identify new therapeutic strategies based on analysis of matrix metalloproteases in the auditory cortex in specific aim 3. An integrated approach based on in vivo electrophysiology, neuroanatomy and pharmacology will be used to address mechanisms of auditory processing deficits and drug effects in reversing these deficits.

Public Health Relevance

Fragile X Syndrome (FXS) is the most common inherited cause of mental impairment and is a leading genetic cause of autism. The proposed studies will identify the brain mechanisms underlying auditory cortical processing deficits that are prevalent symptoms of FXS in humans. We will identify new auditory-based biomarkers and test novel drugs and therapeutic targets to reverse deficits in a mouse model of FXS.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZHD1-DSR-Y (53))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Sw Medical Center Dallas
United States
Zip Code
Erickson, Craig A; Davenport, Matthew H; Schaefer, Tori L et al. (2017) Fragile X targeted pharmacotherapy: lessons learned and future directions. J Neurodev Disord 9:7
Schaefer, Tori L; Davenport, Matthew H; Grainger, Lindsay M et al. (2017) Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety. J Neurodev Disord 9:6
Ethridge, Lauren E; White, Stormi P; Mosconi, Matthew W et al. (2017) Neural synchronization deficits linked to cortical hyper-excitability and auditory hypersensitivity in fragile X syndrome. Mol Autism 8:22
Shou, Guofa; Mosconi, Matthew W; Wang, Jun et al. (2017) Electrophysiological signatures of atypical intrinsic brain connectivity networks in autism. J Neural Eng 14:046010
Wang, Jun; Ethridge, Lauren E; Mosconi, Matthew W et al. (2017) A resting EEG study of neocortical hyperexcitability and altered functional connectivity in fragile X syndrome. J Neurodev Disord 9:11
Sinclair, D; Oranje, B; Razak, K A et al. (2017) Sensory processing in autism spectrum disorders and Fragile X syndrome-From the clinic to animal models. Neurosci Biobehav Rev 76:235-253
Takarae, Yukari; Sweeney, John (2017) Neural Hyperexcitability in Autism Spectrum Disorders. Brain Sci 7:
Guo, Weirui; Molinaro, Gemma; Collins, Katie A et al. (2016) Selective Disruption of Metabotropic Glutamate Receptor 5-Homer Interactions Mimics Phenotypes of Fragile X Syndrome in Mice. J Neurosci 36:2131-47
Lovelace, Jonathan W; Wen, Teresa H; Reinhard, Sarah et al. (2016) Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome. Neurobiol Dis 89:126-35
Ethridge, L E; White, S P; Mosconi, M W et al. (2016) Reduced habituation of auditory evoked potentials indicate cortical hyper-excitability in Fragile X Syndrome. Transl Psychiatry 6:e787

Showing the most recent 10 out of 21 publications